Aims: Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue approved for the treatment of type 2 diabetes. The impact of switching treatment from another GLP-1 receptor agonist (GLP-1RA) to semaglutide was investigated by analyses of exposure-response models.
| INTRODUCTION
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates insulin secretion and inhibits glucagon secretion in a glucose-dependent manner, 1, 2 and is therefore indicated for the treatment of type 2 diabetes mellitus (T2DM). 3, 4 Human GLP-1 is secreted by intestinal L cells in response to food intake. 1, 5 In addition to its antihyperglycaemic effects, GLP-1 has beneficial effects on body weight, unlike many other treatments for T2DM. 6 These effects are modulated by slowing the rate of gastric emptying and enhancing satiety, which in turn leads to reduced energy intake. programme. Semaglutide has 94% amino acid sequence homology to native GLP-1, 8 with three structural modifications that prolong the half-life to approximately 1 week. 8, 9 In two phase 3 trials, semaglutide was compared head-to-head with dulaglutide and exenatide extended release (ER) and was shown to be superior in reducing HbA1c and body weight 10, 11 ( Figure 1 ). However, no studies to date have investigated switching from another GLP-1RA to semaglutide. When contemplating such a switch between GLP-1RAs, it is important to consider the GLP-1RA pharmacokinetics (PK) and the current treatment dosing, once-daily or once-weekly. For instance, the once-daily GLP-1RA liraglutide is cleared from circulation within a few days, 12 whereas exenatide ER provides effective exposure levels for several weeks. 13 We considered that sufficient data were available to develop an exposureresponse model which would provide simulations of the expected treatment outcomes, in terms of changes in HbA1c and body weight, after switching from other GLP-1-RAs to semaglutide.
The aim with the current analyses was to investigate the impact on HbA1c and body weight of switching to semaglutide from other GLP-1RAs (liraglutide, dulaglutide and exenatide ER) and to analyse different dose escalation algorithms depending on the PK of each GLP-1RA.
| SUBJECTS AND METHODS

| Trial data
A summary of the six randomized, controlled phase 2 and 3 trials included in the analyses is presented in Table 1 and estimated mean changes in HbA1c and body weight are shown in Figure 1 . All were conducted in subjects with T2DM.
| Predictions of HbA1c and body weight
The following strategy was applied to predict the HbA1c and body weight time courses when switching from another GLP-1RA to semaglutide.
(1) Published PK models were used to predict the exposure time-course of liraglutide, dulaglutide, exenatide ER and semaglutide for exposure response modelling, including potential switch scenarios. [18] [19] [20] [21] (2) Time-course exposure-response models for semaglutide were developed based on data from the SUSTAIN trials ( Figure 1 and Table S1 ). exposure-response models and the adjusted exposure of different switch scenarios were used to predict HbA1c and body weight outcomes. Each of these steps is described in more detail below. For the analysis of liraglutide, which was compared with semaglutide in the phase 2 trial, 17 we applied a PK model based on data from previous trials that investigated liraglutide doses of 1.8 and 3.0 mg in subjects with overweight or obesity, with or without T2DM. 18 The volume of distribution was based on a clinical pharmacology trial in adults with obesity and without T2DM, 22 to match the peak-totrough ratios observed based on full PK profiles under steady-state conditions.
| Simulation of pharmacokinetics for each treatment
For the analysis of dulaglutide, which was compared with semaglutide in the SUSTAIN 7 phase 3 trial, 10 we applied the population PK model using data from previous trials with weekly doses of dulaglutide between 0.1 and 3 mg in subjects with T2DM. 19 For the analysis of exenatide ER, which was compared with semaglutide in the SUSTAIN 3 phase 3 trial, 11 we applied a clinical pharmacology population PK model, using data from previous trials with single-dose administration of 2.5, 5, 7 and 10 mg of exenatide ER or weekly doses of 0.8 and 2.0 mg in subjects with T2DM. 20 For the analysis of semaglutide, we applied the SUSTAIN population PK model, which used data from five phase 3 trials, SUSTAIN 1, 2, 3, 6 and SUSTAIN-Japan, which investigated weekly semaglutide doses of 0.5 and 1.0 mg in subjects with T2DM. 21 
| HbA1c and body weight time-course models
Time-course models of HbA1c and body weight were developed for semaglutide using data up to week 30, which was the duration of the shortest phase 3 trial, based on the SUSTAIN exposure-response population 23 from four clinical trials, SUSTAIN 1, 2, 3 and SUSTAINJapan. 11, [14] [15] [16] Two of the trials were not included as they either applied daily dosing rather than weekly dosing of semaglutide (phase 2 trial) or did not measure semaglutide concentrations (SUSTAIN 7) (Table S1 ). Maintenance doses of 0.5 and 1.0 mg semaglutide were used, as well as semaglutide 0.25 mg, which was used in the first 4 weeks during dose escalation. The models were mixed-effects indirect response models based on simulated exposure levels at each week (obtained via individual PK parameter estimates based on observed concentration values). A previously published crosssectional E max model was used as a starting point, 23 and for the present work, we explored each covariate factor to ensure that only clear and statistically significant covariates were included. Graphical analysis of model fit to the time-course response data, grouped according to covariates, revealed that a number of the pre-selected covariates could be removed, and additionally, that baseline HbA1c was more likely to influence the E max for body weight than the placebo effect for body weight. The covariates included in the final model for HbA1c were baseline HbA1c and trial effects; those included in the final model for body weight were sex, HbA1c and trial effects. Model fit across demographic variables influencing treatment response is presented in Figure S1 .
The It was not feasible to investigate effects on safety because the exposure-dependent effects on safety, mainly gastrointestinal adverse events, with semaglutide were previously observed primarily during the initiation of treatment 23 and in the present analysis, subjects were already receiving treatment with another GLP-1RA.
| Potency adjustment
The concentration of each GLP-1RA was adjusted by the relative potency to obtain the equivalent semaglutide exposure, that is, the exposure of semaglutide that provides the same response as the original concentration of the GLP-1RA. As potency differences with respect to both body weight and HbA1c effects were expected, the potency adjustment was performed for both endpoints.
The potency adjustment for liraglutide illustrated in Figure S3 was based on joint exposure-response analyses of data concerning liraglutide and semaglutide from a phase 2 dose-finding trial 17 For dulaglutide and exenatide ER, the simulations for potency adjustment were based on a typical subject approach, performed in the same way as the simulated switch scenarios were performed, to ensure that the differences in response matched specific trials. For dulaglutide, the trial factor and potency adjustment was derived, to ensure that the model predicted the correct effects at Week 28 (efficacy outcomes were not measured at Week 30) for dulaglutide and semaglutide from the SUSTAIN 7 trial. 10 For exenatide ER, the potency adjustment was derived to match the effects at Week 30 for exenatide ER and semaglutide from the SUSTAIN 3 trial. 11 The potency adjustment for dulaglutide and exenatide ER with respect to
HbA1c is shown in Figure 2 . The similar potency adjustments for body weight for both treatments are provided in Figure S4 .
Once the exposure had been potency adjusted, it was possible to use the semaglutide exposure-response model to simulate the outcome of liraglutide, dulaglutide and exenatide ER treatment and to obtain the same results as those observed in the clinical trials. In order to simulate the combined effects with semaglutide when subjects were exposed to two long-acting GLP-1RAs at the same time, it was considered appropriate, as all treatments targeted the same receptor, to apply the sum of the potency-adjusted exposure, that is, the total effective GLP-1RA concentration.
| Simulation of switch scenarios for HbA1c and body weight
A number of scenarios were simulated based on the approach described above. Subjects were assumed to be using stable treatment for 26 weeks with: (1) Simulations were based on a typical subject approach, simulating the median outcome for a population similar to the trial populations of the two phase 3 GLP-1RA comparator trials, SUSTAIN 3 and 7.
10,11
The population was 50% male, with a mean baseline body weight of 95 kg and a mean baseline HbA1c of 8.3%.
| Validation of response predictions
In addition to standard model validation for the prediction of semaglutide response following a switch from other GLP-1RAs that is provided in Appendix S1, the model was validated to provide an accurate time-course prediction for dulaglutide and exenatide ER with respect to HbA1c (Figure 2 ) and body weight ( Figure S4 ). Figure 2 illustrates agreement between the model predictions and the observed HbA1c outcome, confirming key differences between semaglutide, dulaglutide and exenatide ER. First, dulaglutide, in particular the 1.5 mg dose, provided a better outcome immediately after initiation of treatment, with a steeper decrease in the first 10 weeks with dulaglutide 1.5 mg compared to semaglutide; however, at steady state, after completion of semaglutide dose escalation, semaglutide clearly had a greater effect on HbA1c. Second, semaglutide had a greater effect than exenatide ER on HbA1c, both during initiation of treatment and at steady state concentrations.
3 | RESULTS
| Population characteristics
Baseline HbA1c, body weight and background medication of the population included in the analyses are presented in Figure 1 by trial, together with the estimated treatment effects for HbA1c and body weight. Additional baseline characteristics are included in Table 1 .
| Effect of switching from another GLP-1RA to semaglutide
In the exposure-response analyses, the potency-adjusted concentra- The modelled effects on HbA1c during the transition period of switching from another GLP-1RA to semaglutide are summarized in Table 2 .
| Switching from liraglutide to semaglutide
Liraglutide at once-daily doses of 1.2 and 1. 
| Switching from dulaglutide to semaglutide
When switching from the lowest dose of once-weekly dulaglutide, When switching to semaglutide from once-weekly exenatide ER 2.0 mg, the protracted half-life of several weeks of exenatide ER is worth noting. 13 However, based on our analysis, switching to the semaglutide 0.25 mg dose resulted in gradual increases in the total effective GLP-1 concentration and led to a gradual improvement in HbA1c and body weight. We did not simulate tolerability when switching to semaglutide as tolerability depends on many factors, including previous treatment duration and tolerability of the GLP-1RA treatment. 32 In the present simulation, subjects were already receiving finding may be artificial, and as the discrepancies among models were small and were present only at low concentrations, they would not be expected to significantly influence the simulated switch scenarios or the conclusions drawn.
Data on HbA1c and body weight from the SUSTAIN 3 and 7 clinical trials 10, 11 were adequately predicted up to Week 30 in the present analyses. Part of the treatment effects on these endpoints decreased in the clinical trials when approaching 1 year. 10, 11 In the SUSTAIN 3 trial, the reduced effects, which were not incorporated into the present models, appeared more pronounced for exenatide ER compared to semaglutide. 11 Therefore, potentially even greater benefits of switching to semaglutide may be seen in the longer term. Potency-adjusted GLP-1 concentration after switching to semaglutide, starting at a dose of 0.5 mg 13 in potency. Although rate parameters are more likely to be consistent across treatments, 33 it is possible that differences exist in maximal efficacy, reflecting the differences in response seen across therapeutic dose levels for the different GLP-1RAs. Because of the potency calibration method, a different maximal effect for one of the other GLP1-RAs would not change the steady-state response predictions but would lead to some bias in predictions at lower concentrations.
One limitation of our analyses is that data were obtained from different trials with differences in trial design and populations; hence, variability could be an issue. This has been accounted for by the inclusion of trial as a covariate factor, and results are validated by predictions of the direct comparisons of the GLP-1 treatments available from phase 3 trials. The model was able to reflect the data obtained from clinical trials comparing the respective GLP-1RAs, dulaglutide and exenatide ER, to semaglutide. 10, 11 Simulations also provided an indirect comparison between liraglutide and dulaglutide, with similar results as observed in the AWARD-6 trial, in which a mean treatment difference of −0.06%-points was observed for HbA1c. 34 Moreover, in the DURATION 6 trial, a better response by 0.21%-points with liraglutide 1.8 mg was demonstrated, compared with exenatide ER, similar to the predictions based on our analysis. 35 An additional limitation is that our results provide only predictions for the mean outcomes and not for the individual patient. No data are available for the correlation between semaglutide and the other GLP1RAs in parameters for exposure and response, which could predict the variability among patients with regard to the potential benefits of switching to semaglutide. Undoubtedly, differences among patients do exist. However, we believe that the mean outcome will be the most informative when evaluating the potential future outcome for patients who may switch to semaglutide.
In summary, pharmacokinetic and pharmacodynamic differences exist between liraglutide, dulaglutide and exenatide ER, at the approved dose levels, and it is relevant to consider these when switching to semaglutide. Exposure-response modelling can facilitate simulation of HbA1c and weight loss outcomes following a switch from other GLP-1RAs to semaglutide treatment. Significant and clinically relevant improvements in HbA1c and body weight are expected to occur following a switch from any of the other GLP-1RAs to semaglutide.
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